PET imaging has gained significant interest in the field of neuroscience and medicine and there is currently a burgeoning clinical appetite for new PET radiotracers for neuroinflammatory conditions such as Motor Neurone Disease (MND), Parkinson’s disease (PD), Multiple Sclerosis (MS), other neurological diseases, and oncology applications. For this program we aim to set up a local manufacturing hub for the development, production and commercialisation of new imaging agents (18F PET radiotracers) for neurological applications. We will scale up our current [18F] PET radiotracers with Australian Company Cyclotek for bulk manufacturing and commercialisation within Australia, and expand commercialisation of current and future PET tracers globally through our international industry partner Life Molecular Imaging GmbH (LMI). The overall aim of this project is to create novel cost-effective imaging tools for both the Australian and Global networks of local supply-on demand centres for neuroimaging.
|Effective start/end date||10/04/21 → 26/09/25|
Jonathan Baell (Manager)Faculty of Pharmacy and Pharmaceutical Sciences
Andrew Powell (Manager)Faculty of Pharmacy and Pharmaceutical Sciences Faculty Office